Panion reports on safety study in dogs – no untoward effects

Panion Animal Health AB develops a unique gene therapy treatment for dogs with epilepsy. Panion's treatment is based on the gene therapeutic technology that CombiGene has developed and that CombiGene has out licensed to Panion for use within in veterinary medicine.

Panions safety study was conducted under the lead of Associate Professor David Woldbye at University of Copenhagen. The first preliminary results show that all treated dogs have successfully completed the study without observable adverse reactions.

CombiGene wants to take this opportunity to congratulate our colleagues at Panion for this successful study!